CALT News and Press, Calliditas Therapeutics AB From 03/22/22

FLORHAM PARK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Molly Henderson t...

Calliditas Therapeutics (NASDAQ:CALT) said its partner Everest Medicines plans to submit a new drug application (NDA) for kidney disease drug Nefecon in China in the H2 2022. The company said Everest received breakthrough therapy designation in China in December 2020, and have completed enrol...

Updated regulatory plans for NEFECON in China PR Newswire STOCKHOLM , March 18, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that partner Everest Medicines (HKEX 1952.HK) plans to sub...

Calliditas Therapeutics (NASDAQ:CALT) has expanded its licensing agreement with Everest Medicines II Limited to extend the territory covered to include South Korea for an upfront payment of $3M as well as additional payments and royalties related to future potential approvals and co...

Expansion of Everest Medicine's licence agreement to include South Korea PR Newswire STOCKHOLM , March 14, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the company has expanded its l...

Everest Medicines Enters into Agreement with Calliditas Therapeutics, Expanding Territory License to Develop and Commercialize NEFECON in South Korea PR Newswire Deal signals Company's latest efforts to further enhance its international commercial footprint SHA...

Year-End Report, 2021 Calliditas became the first Company to receive accelerated approval in IgA Nephropathy. PR Newswire STOCKHOLM , Feb. 24, 2022 /PRNewswire/ -- "The accelerated approval of TARPEYO was for the indication of reduction of proteinuria, which ...

Calliditas Therapeutics (NASDAQ:CALT) said the first patient was randomized in a phase 2b/3 TRANSFORM study evaluating setanaxib in patients with primary biliary cholangitis (PBC). PBC is a disease in which the bile ducts in the liver are slowly destroyed. The 52-week global st...

First patient randomized in pivotal TRANSFORM study with setanaxib PR Newswire STOCKHOLM , Feb. 15, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the first patient has been randomized...

Calliditas Therapeutics Announces Commercial Availability and Initial Sales of TARPEYO™ PR Newswire STOCKHOLM , Jan. 28, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced the comme...